Bulletin of the American Physical Society
68th Annual Gaseous Electronics Conference/9th International Conference on Reactive Plasmas/33rd Symposium on Plasma Processing
Volume 60, Number 9
Monday–Friday, October 12–16, 2015; Honolulu, Hawaii
Session AM1: Challenge of Plasma Science towards Future Medicine Workshop I |
Hide Abstracts |
Chair: Toshiro Kaneko, Tohoku University Room: 301 B |
Monday, October 12, 2015 1:00PM - 1:05PM |
AM1.00001: Opening Remarks |
Monday, October 12, 2015 1:05PM - 1:35PM |
AM1.00002: Non-thermal Plasma and Oxidative Stress Invited Speaker: Shinya Toyokuni Thermal plasmas and lasers have been used in medicine to cut and ablate tissues and for coagulation. Non-equilibrium atmospheric pressure plasma (NEAPP; non-thermal plasma) is a recently developed, non-thermal technique with possible biomedical applications. Although NEAPP reportedly generates reactive oxygen/nitrogen species, electrons, positive ions, and ultraviolet radiation, few research projects have been conducted to merge this technique with conventional free radical biology. Recently, Prof. Masaru Hori's group (Plasma Nanotechnology Research Center, Nagoya University) developed a NEAPP device with high electron density. Here electron spin resonance revealed hydroxyl radicals as a major product. To merge non-thermal plasma biology with the preexisting free radical biology, we evaluated lipid peroxidation and DNA modifications in various in vitro and ex vivo experiments. Conjugated dienes increased after exposure to linoleic and alfa-linolenic acids. An increase in 2-thiobarbituric acid-reactive substances was also increased after exposure to phosphatidylcholine, liposomes or liver homogenate. Direct exposure to rat liver in medium produced immunohistochemical evidence of 4-hydroxy-2-nonenal- and acrolein-modified proteins. Exposure to plasmid DNA induced dose-dependent single/double strand breaks and increased the amounts of 8-hydroxy-2'-deoxyguanosine and cyclobutane pyrimidine dimers. These results indicate that oxidative biomolecular damage by NEAPP is dose-dependent and thus can be controlled in a site-specific manner. Simultaneous oxidative and UV-specific DNA damage may be useful in cancer treatment. Other recent advancements in the related studies of non-thermal plasma in Nagoya University Graduate School of Medicine will also be discussed.\\[4pt] [1] Okazaki et al. J Clin Biochem Nutr 55: 207, 2014\\[0pt] [2] Toyokuni S et al. FEBS Lett 358: 1, 1995 [Preview Abstract] |
Monday, October 12, 2015 1:35PM - 2:05PM |
AM1.00003: Plasma Sources for Medical Applications - A Comparison of Spot Like Plasmas and Large Area Plasmas Invited Speaker: Klaus-Dieter Weltmann Plasma applications in life science are currently emerging worldwide. Whereas today's commercially available plasma surgical technologies such as argon plasma coagulation (APC) or ablation are mainly based on lethal plasma effects on living systems, the newly emerging therapeutic applications will be based on selective, at least partially non-lethal, possibly stimulating plasma effects on living cells and tissue. Promising results could be obtained by different research groups worldwide revealing a huge potential for the application of low temperature atmospheric pressure plasma in fields such as tissue engineering, healing of chronic wounds, treatment of skin diseases, tumor treatment based on specific induction of apoptotic processes, inhibition of biofilm formation and direct action on biofilms or treatment of dental diseases. The development of suitable and reliable plasma sources for the different therapies requires an in-depth knowledge of their physics, chemistry and parameters. Therefore much basic research still needs to be conducted to minimize risk and to provide a scientific fundament for new plasma-based medical therapies. It is essential to perform a comprehensive assessment of physical and biological experiments to clarify minimum standards for plasma sources for applications in life science and for comparison of different sources. One result is the DIN-SPEC 91315, which is now open for further improvements. This contribution intends to give an overview on the status of commercial cold plasma sources as well as cold plasma sources still under development for medical use. It will discuss needs, prospects and approaches for the characterization of plasmas from different points of view. Regarding the manageability in everyday medical life, atmospheric pressure plasma jets (APPJ) and dielectric barrier discharges (DBD) are of special interest. A comprehensive risk-benefit assessment including the state of the art of commercial sources for medical use will be discussed. [Preview Abstract] |
Monday, October 12, 2015 2:05PM - 2:35PM |
AM1.00004: Plasma Onco-Immunotherapy: Novel Approach to Cancer Treatment Invited Speaker: Alexander Fridman Presentation is reviewing the newest results obtained by researchers of A.J. Drexel Plasma Institute on direct application of non-thermal plasma for direct treatment of different types of cancer by means of specific stimulation of immune system in the frameworks of the so-called onco-immunotherapy. Especial attention is paid to analysis of depth of penetration of different plasma-medical effects, from ROS, RNS, and ions to special biological signaling and immune system related processes. General aspects of the plasma-stimulation of immune system are discussed, pointing out specific medical applications. Most of experiments have been carried out using nanosecond pulsed DBD at low power and relatively low level of treatment doses, guaranteeing non-damage no-toxicity treatment regime. The nanosecond pulsed DBD physics is discussed mostly regarding its space uniformity and control of plasma parameters relevant to plasma medical treatment, and especially relevant to depth of penetration of different plasma medical effects. Detailed mechanism of the plasma-induced onco-immunotherapy has been suggested based upon preliminary in-vitro experiments with DBD treatment of different cancer cells. Sub-elements of this mechanism related to activation of macrophages and dendritic cells, specific stressing of cancer cells and the immunogenic cell death (ICD) are to be discussed based on results of corresponding in-vitro experiments. In-vivo experiments focused on the plasma-induced onco-immunotherapy were carried out in collaboration with medical doctors from Jefferson University hospital of Philadelphia. Todays achievements and nearest future prospective of clinical test focused on plasma-controlled cancer treatment are discussed in conclusion. [Preview Abstract] |
Monday, October 12, 2015 2:35PM - 3:05PM |
AM1.00005: Scientific Reports of Plasma Medicine and its Mechanism for Therapy in Plasma Bioscience Research Center Invited Speaker: Eun Ha Choi Scientific reports of plasma medicine and its basic mechanism for therapy will be introduced, especially, performed in Plasma Bioscience Research Center, Korea. We have investigated enhanced anticancer effect of monocytes and macrophages activated by nonthermal plasma which act as immune-modulator on these immune cells. Further, we investigated the action of the nanosecond pulsed plasma activated media (NPPAM) on the lung cancer cells and its DNA oxidation pathway. We observed OD induced apoptosis on melanocytes G361 cancer cells through DNA damage signaling cascade. We also studied DNA oxidation by extracting DNA from treated cancer cell and analyzed the effects of OD/OH/D$_2$O$_2$/H$_2$O$_2$ on protein modification and oxidation. Additionally, we attempted molecular docking approaches to check the action of D$_2$O$_2$ on the apoptosis related genes. [Preview Abstract] |
Follow Us |
Engage
Become an APS Member |
My APS
Renew Membership |
Information for |
About APSThe American Physical Society (APS) is a non-profit membership organization working to advance the knowledge of physics. |
© 2024 American Physical Society
| All rights reserved | Terms of Use
| Contact Us
Headquarters
1 Physics Ellipse, College Park, MD 20740-3844
(301) 209-3200
Editorial Office
100 Motor Pkwy, Suite 110, Hauppauge, NY 11788
(631) 591-4000
Office of Public Affairs
529 14th St NW, Suite 1050, Washington, D.C. 20045-2001
(202) 662-8700